Search Within

Adam Jacob Schoenfeld

Formats
  1. Meeting Abstract (66)
  2. Journal Article (58)
  3. Review (4)
  4. Correspondence (3)
  5. Editorial (2)
  6. Conference Paper (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Department of Medicine (136)
  2. Hematologic Malignancies, Division of (136)
  3. Solid Tumor Oncology Division (136)
  4. Thoracic Oncology (136)
  5. Weinberg Fellows (136)
  6. Department of Pathology and Laboratory Medicine (54)

More Groups

People
  1. Gregory Riely (38)
  2. Marc Ladanyi (36)
  3. Arielle Elkrief (28)
  4. Charles Rudin (27)
  5. Hira Rizvi (27)
  6. Matthew Hellmann (25)

More People

Years
  1. 2025 (16)
  2. 2024 (33)
  3. 2023 (24)
  4. 2022 (17)
  5. 2021 (18)
  6. 2020 (17)

More Years

Publications
  1. Journal of Thoracic Oncology (33)
  2. Journal of Clinical Oncology (27)
  3. Clinical Cancer Research (13)
  4. Annals of Oncology (9)
  5. Journal for ImmunoTherapy of Cancer (9)
  6. Cancer Research (5)

More Publications

Publishers
  1. Elsevier Inc. (40)
  2. American Society of Clinical Oncology (29)
  3. American Association for Cancer Research (22)
  4. Oxford University Press (10)
  5. Biomed Central Ltd (9)
  6. Nature Publishing Group (7)

More Publishers

Results (136)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospective evaluation of a single-day multidisciplinary clinic for patients with locally advanced non-small cell lung cancer
    Meeting Abstract

    Billing, D. L.; Chaft, J. E.; Jones, D. R.; Daly, R.; Schoenfeld, A. J.; Mueller, B. A.; Preeshagul, I.; Park, B. J.; Iyengar, P.; Gomez, D. R.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and immunotherapy retreatment in patients with metastatic NSCLC who complete at least two years of immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Hong, L.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Awosika, N.; Mollica, L.; Citarella, F.; Gandhi, M.; Elkrief, A.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors
    Meeting Abstract

    Schoenfeld, A. J.; Warner, A. B.; Chesney, J. A.; Thomas, S. S.; Moyers, J. T.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P.; Ramsingh, G.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Genomic correlates of response to chemoimmunotherapy in STK11MUT and KEAP1MUT metastatic non-small cell lung cancer
    Meeting Abstract

    Saini, A.; Elkrief, A.; Hong, L.; Ricciuti, B.; Garbo, E.; Pecci, F.; Makarem, M.; Di Federico, A.; Gandhi, M. M.; Aldea, M.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Machine learning-based clinicogenomic prediction of response to PD-(L)1 inhibition in KRAS altered non-small cell lung cancer
    Meeting Abstract

    Boiarsky, D.; Hong, L.; Ricciuti, B.; Cooper, A.; Saad, M.; Elkrief, A.; Di Federico, A.; Aminu, M.; Rinsurongkawong, W.; Lewis, J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response (HAMMER) in non-small cell lung cancer
    Meeting Abstract

    McMillan, M. T.; Gomez, D. R.; Reyngold, M.; Hajj, C.; O'Brien, D. A. R.; Crane, C. H.; Gönen, M.; Bott, M.; Schoenfeld, A. J.; Romesser, P. B.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • The impact of the time of day of radiotherapy and systemic therapy on disease control in locally advanced non -small cell lung cancer treated with chemoradiation and durvalumab
    Meeting Abstract

    McMillan, M. T.; Shepherd, A. F.; Cooper, A. J.; Schoenfeld, A. J.; Wu, A. J.; Simone, C. B. 2nd; Iyengar, P.; Gelblum, D.; Chaft, J.; Gomez, D. R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
    Meeting Abstract

    Schoenfeld, A. J.; Warner, A. B.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P.; Ramsingh, G.; Prabhakar, P.; more...
    Molecular Therapy (2024)

    Fulltext@MSK | Save
  • Characteristics and outcomes of patients with SMARCA4-deficient undifferentiated thoracic tumors
    Meeting Abstract

    Cooper, A.; Ricciuti, B.; Gagne, A.; Sholl, L.; Di Federico, A.; Awad, M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; Chaft, J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save